Luo Bin, Que Zujun, Lu Xinyi, Qi Dan, Qiao Zhi, Yang Yun, Qian Fangfang, Jiang Yi, Li Yan, Ke Ronghu, Shen Xiaoyun, Xiao Hua, Li Hegen, Wu Erxi, Tian Jianhui
Clinical Oncology Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China.
Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
Biol Proced Online. 2023 Nov 13;25(1):29. doi: 10.1186/s12575-023-00223-0.
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related deaths worldwide, primarily due to its propensity for metastasis. Patients diagnosed with localized primary cancer have higher survival rates than those with metastasis. Thus, it is imperative to discover biomarkers for the early detection of NSCLC and the timely prediction of tumor metastasis to improve patient outcomes.
Here, we utilized an integrated approach to isolate and characterize plasma exosomes from NSCLC patients as well as healthy individuals. We then conducted proteomics analysis and parallel reaction monitoring to identify and validate the top-ranked proteins of plasma exosomes.
Our study revealed that the proteome in exosomes from NSCLC patients with metastasis was distinctly different from that from healthy individuals. The former had larger diameters and lower concentrations of exosomes than the latter. Furthermore, among the 1220 identified exosomal proteins, we identified two distinct panels of biomarkers. The first panel of biomarkers (FGB, FGG, and VWF) showed potential for early NSCLC diagnosis and demonstrated a direct correlation with the survival duration of NSCLC patients. The second panel of biomarkers (CFHR5, C9, and MBL2) emerged as potential biomarkers for assessing NSCLC metastasis, of which CFHR5 alone was significantly associated with the overall survival of NSCLC patients.
These findings underscore the potential of plasma exosomal biomarkers for early NSCLC diagnosis and metastasis prediction. Notably, CFHR5 stands out as a promising prognostic indicator for NSCLC patients. The clinical utility of exosomal biomarkers offers the potential to enhance the management of NSCLC.
非小细胞肺癌（NSCLC）仍然是全球癌症相关死亡的主要原因，主要是由于其转移倾向。被诊断为局限性原发性癌症的患者比有转移的患者生存率更高。因此，发现用于早期检测NSCLC和及时预测肿瘤转移的生物标志物以改善患者预后至关重要。
在此，我们采用综合方法从NSCLC患者以及健康个体中分离和表征血浆外泌体。然后我们进行了蛋白质组学分析和平行反应监测，以鉴定和验证血浆外泌体中排名靠前的蛋白质。
我们的研究表明，有转移的NSCLC患者外泌体中的蛋白质组与健康个体的明显不同。前者的外泌体直径更大、浓度更低。此外，在鉴定出的1220种外泌体蛋白质中，我们确定了两组不同的生物标志物。第一组生物标志物（FGB、FGG和VWF）显示出早期NSCLC诊断的潜力，并与NSCLC患者的生存时间直接相关。第二组生物标志物（CFHR5、C9和MBL2）成为评估NSCLC转移的潜在生物标志物，其中仅CFHR5与NSCLC患者的总生存显著相关。
这些发现强调了血浆外泌体生物标志物在早期NSCLC诊断和转移预测方面的潜力。值得注意的是，CFHR5是NSCLC患者一个有前景的预后指标。外泌体生物标志物的临床应用为加强NSCLC的管理提供了潜力。
